VanEck Biotech ETF BBH
Set alert
257.98 USD +1.08 +0.42%
At close · Oct 30
257.98 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
256.52 Day range 262.60
178.09 52-week range 257.98
- YTD
- +36.31%
- 1 year
- +44.86%
- Open
- 259.30
- Prev close
- 256.90
- Mkt cap
- 523.17M
- Vol
- 32.26K
- Avg vol
- 10.78K
- EPS
- 8.48
- P/E
- 30.42
- Div yield
- 0.00%
More statistics
- Low
- 256.52
- High
- 262.60
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 167.95
- 200-d avg
- 169.82
Key statistics
- Market cap
- 0
- Enterprise value
- 0
- Trailing P/E
- 29.88
- Forward P/E
- 0.00
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.00
- EPS (TTM)
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Shares outstanding
- 0
- Short % of float
- 0.00%
- 50-day average
- 167.95
- 200-day average
- 169.82
About VanEck Biotech ETF
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index includes common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
News
- ETFs That You May Consider Amid a Strengthening Biotech Outlook
- Why Healthcare ETFs Are Hovering Around One-Year Highs
- Biotech Giants vs. Emerging Innovators: Which ETF Is the Better Buy?
- Biotech ETF (BBH) Hits New 52-Week High
- BBH Capital Partners Private Equity Exits The Granite Group
- Better Biotechnology ETF: First Trust FBT vs. VanEck BBH
- Better Healthcare ETF: VanEck's Biotech-Focused BBH vs. State Street's XPH Targeting Pharma
- Fidelity Healthcare ETF (FHLC) vs. VanEck Biotech ETF (BBH): Which Fund Is the Better Buy?
- Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate
- Should You Invest in the VanEck Biotech ETF (BBH)?
Your note
Sign in to keep a note on BBH — it syncs with the Stock Master app.